Ranking results:

Past rankings:

Ranking timeline:

Project Participation Performance(2010-01-01 - 2024-12-31 ):

Total Project Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:

Leadership:

Total number of projects: 3
As coordinator: 0
As participant: 3
Sole participant: 0
Coordinator / Participant Ratio: 0^*

^*Ratio includes only projects with > 2 partners

Summary:

	Total project funding [€]:			Projects [No]:
Year:	coordinator^*	participant^*	per partner	as coordinator	as participant
2017	0	25.109.415	9.284		2
2013	0	5.498.829	2.505.885		1

^*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:

Institution:	Projects [No]:
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD	3
EXPRES2ION BIOTECHNOLOGIES APS	2
GENOME RESEARCH	2
INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT	2
NOVAVAX AB	2
OSIVAX SAS	2
ACADEMISCH ZIEKENHUIS LEIDEN	1
EUROPEAN VACCINE INITIATIVE EEIG	1
JAMES COOK UNIVERSITY	1
JANSSEN VACCINES & PREVENTION BV	1
MEDICAL RESEARCH COUNCIL	1
PRECLIN BIOSYSTEMS	1
PROGRAM FOR APPROPRIATE TECHNOLOGYIN HEALTH	1
SORBONNE UNIVERSITE	1
STATENS SERUM INSTITUT	1
STICHTING KATHOLIEKE UNIVERSITEIT	1
THE UNIVERSITY OF EDINBURGH	1
UNITED KINGDOM RESEARCH AND INNOVATION	1
UNIVERSITE DE LAUSANNE	1
UNIVERSITE PIERRE ET MARIE CURIE PARIS 6	1

Constancy:

Total number of partners: 27
Partner loyalty:
Frequent Partner: (> 2 projects): 3
Rare Partner: 24
Frequent / Rare Partner Ratio: 0.13

Project overview:

Start date	Project	acronym	role	funding	partners
2017-01-01	Optimizing a deployable high efficacy malaria vaccine	OptiMalVax	participant	20.050.441	18
2017-01-01	Development of Effective Vaccines against Multiple Lifecycle Stages of Plasmodium vivax malaria	MultiViVax	participant	5.058.974	8
2013-09-01	comBinig cELLular and humoral immunE RespOnses as a vaccine strategy against staPHhylOcoccus aureus pathogeN	BELLEROPHON	participant	5.498.829	4

Alias institution names:

IMAXIO

IMAXIO SA - France